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Department of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
Fas-mediated apoptosis contributes to physiological and pathological cellular processes, 
such as differentiation and survival. In particular, the roles of Fas in immune cells are com-
plex and critical for the maintenance of immune tolerance. The precise pathways and 
unique functions associated with Fas/FasL-mediated signaling in the immune system 
are known. The dual character of Fas/FasL-mediated immune regulation that induces 
beneficial or harmful effects is associated with the onset or development of immune 
disorders. Studies on mutations in genes encoding Fas and FasL gene of humans and 
mice contributed to our understanding of the pathogenesis of autoimmune diseases. 
Here, we review the opposing functions of Fas/FasL-mediated signaling, bilateral effects 
of Fas/FasL on in immune cells, and complex pathogenesis of autoimmunity mediated 
by Fas/FasL.
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iNTRODUCTiON
Fas receptor (CD95, tumor necrosis factor receptor superfamily member 6) is a death receptor 
(DR) localized on the surface of various cells, which triggers a signal transduction pathway leading 
to apoptosis (1, 2). The interaction of Fas with its ligand FasL (FasL/CD95L) regulates numerous 
physiological and pathological processes that are mediated through programmed cell death (3). The 
beneficial and harmful effects of Fas-mediated apoptosis on the immune system were identified after 
the discovery (4–6). Moreover, signaling downstream of Fas is intricately regulated by numerous 
pathway components (7–9).
MRL-lpr/lpr mice bear mutations in the gene encoding Fas and serve as a widely used model 
for autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), 
Sjögren’s syndrome (SS), and autoimmune lymphoproliferation syndrome (ALPS) (10, 11). Fas-
mediated apoptosis of peripheral T cells, which represents a key mechanism that maintains immu-
nological tolerance, is impaired in MRL-lpr/lpr mice. This mechanism, known as activation-induced 
cell death (AICD), deletes overactivated or autoreactive T cells in the periphery (12). The deletion of 
peripheral T cells by AICD is impaired in MRL-lpr/lpr mice, leading to increased autoreactive T cells 
that trigger the induction of autoimmune lesions in multiple organs (10, 13). Moreover, mutations 
in the gene encoding Fas occur in patients with ALPS (14, 15).
By contrast, FasL expression on the cell surface is specific to the immune system. For example, 
FasL expression by T cells is associated with their activation (4). FasL is unstable because it is shed 
Abbreviations: AICD, activation-induced cell death; ALPS, autoimmune lymphoproliferation syndrome; TNF-α, tumor 
necrosis factor-alpha; TRAIL, TNF-related apoptosis-inducing ligand; TRAF2, TNF receptor-associating factor 2; TCR, T-cell 
receptor; cFLIP, caspase-8-like inhibitory protein, NF-κB, nuclear factor-kappa β.
FigURe 1 | Apoptotic signaling via Fas/FasL. Engagement of the death receptors (DRs) with their cognate ligands, such as FasL/CD95L, tumor necrosis 
factor-alpha (TNF-α), lymphotoxin-alpha (LT-α), TNF-like protein-1A (TL1A), and Apo2L/TNF-related apoptosis-inducing ligand (TRAIL), and their receptors promotes 
recruitment and activation of the apoptosis-initiating proteases, caspase-8, and caspase-10 and induces transcriptional events leading to nuclear factor-kappa β 
(NF-κB)-dependent pro-inflammatory cytokine expression.
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from the cell surface through the action of certain enzymes 
(16, 17). When soluble FasL (sFasL) binds to Fas, cell proliferation, 
but not apoptosis, is induced (18). Mice with the gld/gld genotype 
bear mutations in the gene encoding FasL, and they are widely 
used as a model of autoimmune disease (19, 20). Moreover, 
mutations of the gene encoding FasL occur in patients with 
ALPS (14, 15, 21), and FasL is expressed by thyroid, endothelial, 
and corneal cells (22–24). Expression of FasL by cells residing in 
“immunoprivileged site” protects them from attack by activated 
or autoreactive lymphocytes (5).
This review describes the multiple functions of Fas/FasL in the 
immune system with focus on duality of Fas/FasL signaling in 
immune regulation and autoimmunity.
Fas-MeDiATeD APOPTOSiS
Fas protein has 319 amino acids and the predicted molecular 
weight is 48  kDa. The mature protein is divided into three 
domains: an extracellular domain, a transmembrane domain, 
and a cytoplasmic domain. The extracellular domain consists 
of 157 amino acids with cysteine-rich domain. The transmem-
brane and cytoplasmic domains have 17 and 145 amino acids, 
respectively. Exons 1 through 5 encode the extracellular region. 
Exon 6 encodes the transmembrane region. Exons 7–9 encode 
the intracellular region (1, 2).
Extrinsic and intrinsic pathways are the major DR-mediated 
pathways of apoptosis. Engagement of the DRs with cognate 
ligands including FasL induces recruitment and activation of the 
apoptosis-initiating proteases, such as caspase-8 and caspase-10, 
and then induces apoptosis through various molecules. By 
contrast, the binding of some cognate ligands to DR triggers 
transcriptional events leading to nuclear factor-kappa β (NF-
κB)- or activator protein-1 (AP-1)-dependent pro-inflammatory 
cytokine expression (Figure  1). DRs, which are members of a 
subset of the TNF receptor superfamily known as death receptors, 
possess a cytoplasmic death domain (DD). Fas-mediated apop-
tosis proceeds through the extrinsic pathway via the binding to 
their respective receptors of ligands, such as FasL, tumor necrosis 
factor-alpha (TNF-α), lymphotoxin-alpha (LT-α), TNF-like 
protein-1A (TL1A), and Apo2L/TNF-related apoptosis-inducing 
ligand (TRAIL) (Figure 1). FasL is the ligand for the Fas receptor. 
TNF-α and LT-α are ligands for the TNF superfamily member 
1A (TNFR1), TL1A is a ligand for TNF receptor superfamily 
member 25 (DR3), and TRAIL is a ligand for the TNF receptor 
superfamily member 10a (DR4/TRAIL-R1) or tumor necrosis 
factor receptor superfamily member 10b (DR5/TRAIL-R2). 
These receptors are members of a subset of the TNF receptor 
super family known as DRs. Engagement of DRs of their cognate 
ligands promotes recruitment and activation of the apoptosis-
initiating proteases caspase-8 and caspase-10 within membrane 
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receptor complexes (25). Apoptosis induced by the engagement 
of the DRs by their cognate ligands is well understood (26–29) 
(Figure 1).
Binding of DRs to their cognate ligands recruits one of two 
pivotal DD-containing adaptor proteins: Fas-associated protein 
with DD (FADD) or TNF receptor-associated DD (TRADD) 
(Figure  1). FADD controls cell death by recruiting caspase-8 
and caspase-10, TRADD controls non-apoptotic functions by 
recruiting the DD-containing kinase receptor-interacting pro-
tein-1 (30), and the E3 ubiquitin ligases TNF receptor-associating 
factor 2 (TRAF2) and cellular inhibitor of apoptosis proteins 
(31). TRADD signaling activates phosphorylation cascades 
comprising the IKK kinase complex, which phosphorylates the 
inhibitor of NF-κB and the mitogen-activated protein kinases, 
c-jun N-terminal kinase (JNK), and p38 (Figure 1). The recruit-
ing events initiate a transcriptional program to express genes that 
induce the synthesis of mediators of inflammation (7–9). DRs 
can be divided into two categories based on the primary adap-
tor protein they bind to Fas/CD95/APO-1, DR4/TRAIL-R1 and 
DR5/TRAIL-R2 bind FADD and mediate mainly proapoptotic 
functions (Figure 1). By contrast, TNFR1 and DR3 bind TRADD 
and mediate mainly pro-inflammatory and immune-stimulatory 
activities (7–9) (Figure 1).
In the Fas-mediated apoptotic pathway, binding of FasL 
drives Fas clustering and binding of Fas to FADD. FADD 
recruits caspase-8 and caspase-10 to form the death-inducing 
signaling complex (DISC) (25). DISC is activated by specific 
post-translational modifications of the DR, such as palmitoyla-
tion and O-linked glycosylation (32, 33). The DISC mediates 
autocatalytic processing and activation of caspase-8 and 
caspase-10, which propagate the death signal either through 
proteolysis of effector caspases such as caspases-3, caspase-6, 
and caspase-7. In type I cells such as thymocytes, processing 
by effector caspases is sufficient to induce apoptosis (Figure 1). 
By contrast, apoptosis requires caspase-8-mediated cleavage 
of BH3-interacting domain death agonist (Bid), which is a 
BH3-only protein that can promote the permeabilization of 
mitochondrial outer membranes and release of cytochrome c 
in type II cells such as B  cells (Figure  1). Upon release from 
mitochondria, cytochrome c acts as a cofactor for the assembly 
of a cytosolic caspase-activating complex called the apoptosome, 
which propagates the caspase activation cascade (33). Thus, 
Fas signal has dual pathways of apoptosis and non-apoptosis 
in various cells.
Fas-MeDiATeD T CeLL iMMUNe 
RegULATiON
The negative selection of autoreactive T  cells in thymus is 
regulated by strong T cell signals that induce apoptosis through 
Bcl-2-interacting mediator of cell death (Bim), but not Fas (34). 
By contrast, apoptosis of activated peripheral T cells is controlled 
by the intrinsic and extrinsic pathways (34). Antigen stimulation 
via the T-cell receptor (TCR) contributes to antigen-specific 
T cell responses related to cell survival. TCR and Fas signaling 
are linked, and the AICD of peripheral T cells is controlled by 
interaction between TCR and Fas signaling (34).
Following TCR ligation, signaling through CD3 complex leads 
to recruitment of signaling molecules such as lymphocyte-specific 
protein tyrosine kinase (LCK), phosphorylation of ζ-chain-
associated protein kinase 70 (ZAP70), linker for activation of 
T cells (LAT), phospholipase Cγ1, VAV, SH2-domain-containing 
leukocyte protein 76, and protein kinase Cθ, in coordination with 
costimulatory molecules such as CD28 and CD4 (35, 36) (Figure 2).
Homeostasis of peripheral T  cells is maintained by three 
mechanisms as follows: unresponsiveness (anergy) of T  cells, 
suppression by regulatory T cells, and AICD (37). AICD is initi-
ated by repeated stimulation of the TCR through Fas-mediated 
apoptosis to control the effector T-cell population (38). Further, 
AICD is induced through the interaction between Fas and FasL, 
and activated T  cells expressing Fas and FasL are killed either 
though suicide or by mutual interaction (39, 40). During the 
immune responses, antigen-stimulated effector T cells are acti-
vated to produce various inflammatory cytokines and growth 
factors. Although the tuning of TCR signaling is controlled by 
costimulatory molecules such as CD28 and programmed cell 
death protein-1 (41), the system that declines the activated T cells 
maintains peripheral tolerance. Overactivated effector T cells are 
harmful to the immune system, and should be deleted from the 
periphery. Therefore, AICD induced by Fas-mediated apoptosis 
plays a potent role in the peripheral immune system (37).
Moreover, impairment of AICD contributes to the onset 
or development of autoimmunity. Numerous studies of lpr/
lpr or gld/gld mice focused on the relationship between AICD 
of peripheral T  cells and autoimmunity (10, 11, 19, 20). These 
studies found that impaired AICD in lpr/lpr or gld/gld mice leads 
to T cell dysfunctions and the onset of autoimmune lesions in 
multiple organs (10, 11, 19, 20). Evidence indicates that autore-
active T cells are abundant in the periphery of lpr/lpr or gld/gld 
mice as well as in patients with ALPS (10, 11, 19, 20). By contrast, 
Fas-independent T cell apoptosis is induced by the direct interac-
tion between TRAIL-R2 on T cells and TRAIL on Fas-deficient 
dendritic cells in MRL-lpr/lpr mice (42). Thus, member of the 
TNFR family, including Fas and TRAIL-R2, likely play a key role 
in the maintenance of peripheral immune tolerance.
By contrast, Fas mediates apoptotic and non-apoptotic path-
ways (28). Acting downstream of cellular caspase-8-like inhibi-
tory protein (cFLIP) and TRAF2 in the Fas signaling pathway, 
T-cell proliferation is induced through NF-κB activation (43) 
(Figure 2). The cFLIP N-terminal cleavage products p43-FLIP 
and p22-FLIP induce NF-κB activation by binding to the IKK 
complex (44, 45) (Figure 2). Further, overexpression of cFLIP 
inhibits Fas-induced apoptosis of activated T  cells (46, 47). 
Moreover, Fas signaling regulates peripheral T cell homeostasis 
by modulating the equilibrium between proliferation and cell 
death, for example, in naive and memory T  cell subsets (48). 
Therefore, homeostasis of peripheral T cells may be maintained 
by the dual outocomes of FasL/Fas signaling.
Fas-MeDiATeD B CeLL iMMUNe 
RegULATiON
The first report of the expression of FasL on the surface of B cells 
of wild-type mice but not from gld/gld mice demonstrated that 
FigURe 2 | interaction between Fas receptor and T-cell receptor (TCR) pathway. Fas-mediated apoptosis is initiated by the recruitment of Fas-associated 
protein with DD (FADD). FADD then recruits caspase-8 and forms a homodimer with caspase-8. Caspase-8 homodimers lead to the activation of caspase-3 and 
induce apoptosis. FADD also recruits caspase-8-like inhibitory protein (cFLIP) and form a heterodimer with caspase-8. cFLIP interacts with the IKK complex leading 
to nuclear factor-kappa β (NF-κB) activation. By contrast, ligation of TCR leads to recruitment of LCK and activation of ζ-chain-associated protein kinase 70 (ZAP70), 
which in turn induces tyrosine phosphorylation of linker for activation of T cells (LAT) and SH2-domain-containing leukocyte protein 76 (SLP76). SLP76 also induces 
the formation of complex that contains CARD-MAGUK protein-1 (CARMA1), BCL-10, and MALT1. BCL-10 and MALT1 are associated with active caspase-8 and 
cFLIP to promote the induction of antiapoptotic NF-κB target genes.
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activation of mouse B cells leads to the expression of FasL and 
killing of Fas-expressing target cells by B  cells (49). Further, 
surface-localized FasL is expressed by human and mouse 
B cells, and the abnormal function of FasL+ killer B cells leads to 
a novel target for immune modulation in many disease settings 
(50–52). Moreover, reduction of the number of FasL+CD5+ 
B cells is associated with exacerbated severity of arthritis and 
inhibits T-cell death in a TCR transgenic mouse model with 
collagen-induced arthritis (53). Deficiency of the FasL/Fas 
signaling pathway in humans leads to ALPS, which is most 
often manifested as autoimmune hemolytic anemia, throm-
bocytopenia, or leukocytopenia, caused by cell-type specific 
autoantibody production (54, 55). Thus, FasL/Fas interactions 
play a critical role in regulating the production of pathogenic 
autoantibodies. The killer B cells that produce these autoanti-
bodies may represent a novel modality for inducing T-cell death 
to treat autoimmunity.
Moreover, the expression of FasL on B  cells of individuals 
infected by human immunodeficiency virus (HIV) (56) and the 
induction of Epstein–Barr virus of FasL expression by B  cells 
markedly increases the sensitivity of Th cells to Fas-mediated T cell 
apoptosis (57). Although these data suggest that FasL expression 
by B cells might play a pathogenic role by inducing T cell death 
during viral infections, this hypothesis was not explored.
Findings that FasL+ B-chronic lymphocytic leukemia 
(B-CLL) cells kill a susceptible CD4+ T-cell leukemia cell line 
provided the first direct evidence implicating B  cells in the 
induction of T  cell apoptosis (52). FasL expression frequently 
occurs in patients with the aggressive form of B-CLL as well as 
in other human B-cell leukemias and lymphomas, most notably, 
multiple myeloma (58, 59). These results suggest that killer 
B cells induced by viral infections and tumor cells play a crucial 
role in the ability of virus-infected or cancer cells to evade the 
host’s immune system.
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By contrast, Fas is highly expressed in activated and germinal 
center (GC) B  cells. B  cell-specific Fas deficiency is associated 
with the onset of autoimmunity (60), suggesting that Fas prevents 
the development of self-reactive GC B cells that escape normal 
regulatory controls and produce high amounts of immuno-
globulin and autoantibodies (60, 61). Further, MRL-lpr/lpr mice 
produce circulating autoantibodies, such as rheumatoid factor 
as well as those against a single- and double-strand DNA and 
nuclear antigens (62, 63), indicating the contribution of FasL/Fas 
signaling in B cells to cellular processes such as differentiation, 
proliferation, death, and immunoglobulin production. Thus, Fas 
signal in B cell plays potent roles in the function and the patho-
genesis of immune disorders.
UNiQUe ROLeS OF FasL
FasL is a homotrimeric membrane protein that belongs to the 
TNF superfamily including CD178, CD95L, and apoptosis anti-
gen-1 (Apo-1) ligand. Human FasL shares 81 and 78% amino acid 
sequence identity with its mouse and rat homologs, respectively. 
FasL comprises a single transmembrane domain, an intracellular 
domain harboring a proline-rich domain, and an extracellular 
domain. The latter contains an oligomerization domain required 
for oligomerization (64).
FasL expression on activated T cells is induced by stimulation 
via TCR, costimulatory molecules, and cytokine receptors (65). 
FasL expression is regulated by several transcription factors, 
including NF-κB, nuclear factor of activated T  cells (NF-AT), 
early growth response gene family transcription factors, c-Myc, 
AP-1, secretory protein-1, and interferon regulatory factors 
(66–72).
Matrix metalloproteinase-7 (matrilysin) cleaves FasL to 
generate sFasL, which is released into the extracellular milieu 
(73). Abnormal levels of trimeric sFasL (73, 74) are detected in 
sera from patients with large granular lymphocytic leukemia and 
natural killer (NK) cell lymphoma (3), and other cancers as well 
as patients with SLE (75). The level of serum sFasL correlated 
with disease progression (3, 75) suggesting that sFasL induces 
the apoptosis of Fas+ T  cells to evade immune surveillance. 
Thus, sFasL possesses proapoptotic and antiapoptotic properties 
depending of cell type and the microenvironment.
Apoptosis induced by FasL requires extensive oligomerization 
of the Fas receptor to activate the DISC (76), and membrane-bound 
FasL (mFasL) and sFasL can bind the Fas receptor. However, the 
naturally cleaved form of sFasL does not form oligomers with 
the Fas receptor, and therefore sFasL fails to induce apoptosis. 
Further, sFasL inhibits mFasL-mediated apoptosis through steric 
hindrance of its binding to the Fas receptor, indicating that mFas 
and sFasL have opposite functions that affect cell survival (77–79). 
For example, sFasL shed by a disintegrin and metalloproteinases 
or MMPs induces proliferation of fibroblast-like synoviocytes in 
patients with RA through activation of v-akt murine thymoma 
viral oncogene homolog (Akt1), extracellular signal-regulated 
kinase, and JNK (Figure 3) (80). Thus, sFasL has dual functions 
for cell death and survival.
Loss-of-function mutations in the genes encoding murine and 
human FasL causes a phenotype similar to that of patients with 
lymphadenopathy and autoimmune disease because of decreased 
apoptosis in Fas+CD4−CD8− T lymphocytes and the production 
of autoantibodies (81, 82). In patients with ALPS, germline muta-
tions of FasL gene are associated with defective apoptosis (83). 
Patients with rare heterozygous FasL gene mutations are classified 
as type Ib-ALPS (84).
The tissue distribution of FasL, which is predominantly 
expressed by activated T cells and NK cells, is limited (3). FasL is 
constitutively expressed by stromal cells of the retina and Sertoli 
cells of the testis, respectively, which are immunoprivileged 
tissues. In such tissues, FasL expression leads to the death of 
invading Fas+ cells. The susceptibility of the eyes of gld/gld mice to 
inflammation (85) and their rejection of corneal allografts prove 
that FasL plays an important role in sites of immune privilege (24). 
The ocular immune privilege is believed to be one mechanism 
by which the visual axis is protected from dangerous immune 
reactions. Therefore, immunoprivileged site is maintained by the 
sequestration of any antigens, the lack of lymphatic damage, and 
the blood-tissue barrier (5). In addition, both Fas and FasL are 
present on thyroid cells in patients with autoimmune thyroiditis 
(Hashimoto’s thyroiditis) (22). This suggests that Fas/FasL inter-
actions among thyroid cells contribute to the pathogenesis of 
autoimmune thyroiditis with tissue destruction (22).
FasL is expressed in tumors such as colorectal carcinomas, 
melanomas, head and neck carcinomas, and myelomas (86). 
The level of FasL produced by non-immune cells can induce 
apoptosis in Fas+ T cells that recognize tissue-specific antigens to 
evade immune surveillance (86). Moreover, a variety of cell types 
can express FasL in response to different stimulatory conditions, 
including macrophages infected with HIV, hepatocytes treated 
with ethanol, leukemia cells exposed to chemotherapy drugs, as 
well as cancer cells (87, 88). Thus, the unique functions of FasL 
contribute to various physiological or pathological processes that 
are not associated with the immune system.
THe Fas/FasL SYSTeM iN 
AUTOiMMUNiTY
The contribution of Fas-mediated apoptosis to the onset and 
development of autoimmunity was established by studies of 
patients with autoimmune diseases and animal models (14, 15, 
89, 90). ALPS is an inherited disorder of the systemic immune 
system that involves a spontaneous mutation in the Fas or 
FasL gene (14, 15, 21). Approximately two-thirds of patients 
with ALPS bear mutations in the gene encoding Fas (type Ia) 
(91, 92). By contrast, there are few reports of mutations in the 
genes encoding FasL gene (type Ib) and caspase-10 gene (ALPS 
type IIa) (92–95), and these mutations are not detected in 
patients with ALPS type III (96).
The clinical features of patients with ALPS are splenomegaly, 
lymphadenopathy, and hepatomegaly, which are caused by the 
accumulation of polyclonal lymphocytes as well as autoimmune 
lesions in multiple organs. The risk of malignant lymphoma is 
increased in patients with ALPS (97). Peripheral T cells express-
ing TCRα/β, but not CD4 and CD8 [CD4−CD8− double negative 
(DN)], proliferate, and their population expands in the patients 
with ALPS due to an impaired AICD caused by a defect in the 
FigURe 3 | Differential signaling pathway by membrane-bound FasL (mFasL) and soluble FasL (sFasL). mFasL leads to the recruitment of FADD and 
activates caspase pathways. mFas promotes apoptosis. mFasL is shed by a disintegrin and metalloproteinases (ADAM) or MMPs in the pathological or physiological 
condition. For instance, sFasL strongly activates extracellular signal-regulated kinase (ERK), PI3K/Akt, and c-jun N-terminal kinase (JNK) to induce proliferation and 
inhibit apoptotic activity of the fibroblast-like synoviocytes. Differential signal by the engagement of sFasL is determined by the cell type and the pathologic condition.
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Fas/FasL system (98). Further, the abnormal programming of 
Fas-deficient T cells before the DN T-stage is caused by impaired 
signaling through the mTOR pathway (99). Moreover, a defect in 
B-cell selection occurs in patients with ALPS, which is caused by 
impaired class-switch recombination and somatic hypermutation 
of the genes encoding immunoglobulins (100). Polymorphisms 
in the genes encoding Fas and FasL are associated with the sus-
ceptibility and severity of autoimmune lesions in patients with 
RA (101, 102) as well as in patients with primary SS (103).
To understand the mechanism of Fas/FasL-mediated apoptosis 
in vivo, MRL-lpr/lpr mice were used as a model of susceptibility 
to autoimmune disease before spontaneous mutation of the gene 
encoding Fas was discovered to affect the onset of autoimmunity 
in the mice (10). Further, gld/gld mice bearing a spontaneous 
mutation of the gene encoding FasL are employed as a model for 
autoimmune disease as well (19, 20). Lymphoproliferative lesions 
in lpr/lpr and gld/gld mice demonstrate that Fas/FasL-mediated 
apoptosis plays a critical role in controlling the maintenance 
of peripheral lymphocytes. In particular, Fas/FasL-mediated 
apoptosis contributes to the AICD of T  cells in the periphery 
(4). Moreover, peripheral T  cell apoptosis is induced by FasL 
expression by macrophages, and apoptotic T cells are promptly 
phagocytosed by these macrophages, depending on their level 
of Fas expression (104). In these experiments, normal T cells of 
C57BL/6 (B6) mice were engulfed by macrophages of B6-lpr/lpr 
mice, which lead to enhanced Fas expression by donor T  cells 
through IFN-γ/IFN-γ-receptor signaling (104). These findings 
revealed that the control of Fas expression by macrophages plays 
an essential role in maintaining T cell homeostasis in the periph-
eral immune system.
By contrast, the expression of Fas or FasL occurs in target 
organs of patients with autoimmune diseases and in animal 
models (105, 106). High levels of sFasL are present in the 
synovial fluid of patients with RA (107), which may be associ-
ated with Fas-mediated apoptosis of synovial cells, but not the 
AICD of T  cells. Further, sFasL present in the synovial fluid 
of patients with RA inhibits angiogenesis in RA lesions (108). 
These observations are consistent with decreased levels of FasL 
mRNA expression in lacrimal gland tissues and peripheral blood 
lymphocytes as well as increased levels of Fas and FasL in salivary 
gland tissues of patients with SS (109, 110). These findings impli-
cate Fas-mediated apoptosis in the destruction of target salivary 
gland tissue.
When we treated SS model mice with an anti-murine FasL-
specific monoclonal antibody to protect against Fas-mediated 
apoptosis of the target salivary gland cells (111), we unexpectedly 
observed exacerbation of the autoimmune lesions in the salivary 
and lacrimal glands (111). We found that sFasL is processed by 
TABLe 1 | Relationship between cell type and Fas/FasL expression.
Cell type Fas/FasL 
expression
Remarks
T cell Fas+, FasL+ Activation-induced cell death, 
autoimmune lymphoproliferation 
syndrome (ALPS), autoimmunity
B cell Fas+, FasL+ ALPS, collagen-induced arthritis, virus 
infection, germinal center, B-chronic 
lymphocytic leukemia
Natural killer cell FasL+ Tumor immunity
Macrophage Fas+, FasL+ Peripheral immune tolerance
Thyrocyte Fas+, FasL+ Hashimoto’s thyroiditis, immune privilege
Sertoli cell FasL+ Immune privilege
Salivary gland cell Fas+ Sjögren’s syndrome
Corneal cell FasL+ Immune privilege
Synovial cell, fluid Fas+, soluble 
FasL
Rheumatoid arthritis
7
Yamada et al. Fas Signal in Peripheral Immune Tolerance
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 403
autoantigen-specific CD4+ T cells concomitant with metallopro-
teinase-9 expression (65, 111), indicating that increased sFasL 
expression inhibits the normal AICD of T cells and leads to the 
proliferation of autoreactive T cells in this SS model. Moreover, 
although mFasL, but not sFasL, is essential for cytotoxic activity 
that guards against lymphadenopathy and autoimmunity (29), 
it remains unclear whether the relationship between mFasL and 
sFasL contributes to the molecular mechanisms of AICD. Thus, 
the impairment of Fas/FasL system in the peripheral immune 
tolerance considerably contributes to the onset or development 
of a lot of autoimmune diseases.
CONCLUDiNg ReMARKS
Some examples regarding the relationship between various 
cells and Fas/FasL expression are listed in Table  1. Numerous 
molecules precisely regulate Fas-mediated apoptosis through 
complicated signaling cascades. Apoptotic and antiapoptotic 
signaling pathways in T  cells are controlled by the interaction 
between TCR and Fas signaling pathways and the expression of 
FasL. Further, the Fas/FasL system plays potent roles in B  cell 
biology. The unique functions of FasL contribute to tumorgen-
esis, infection, immune disorders as well as to the outcomes of 
tissue transplantation. Finally, the multiple functions of Fas/
FasL-mediated regulation maintain immune tolerance.
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